Suven Life Sciences has successfully concluded patient enrollment for the global Phase-3 clinical trial of its drug candidate, Masupirdine (SUVN-502), aimed at treating agitation associated with Alzheimer’s Dementia. The study exceeded its target by enrolling 424 patients across the USA and Europe. This achievement marks a key de-risking milestone for the company’s flagship R&D program. Investors should now monitor the trial timeline, with topline results anticipated by May 2027.
Suven Life Sciences Concludes Enrollment for Phase-3 Alzheimer’s Trial
424 patients randomized for Masupirdine study; topline results expected in May 2027.
Reader Takeaway: Successful trial recruitment serves as a major de-risking milestone, shifting focus toward clinical efficacy results.
What just happened
Suven Life Sciences announced the completion of patient enrollment for the global Phase-3 study of Masupirdine (SUVN-502), a treatment for agitation associated with Alzheimer’s Dementia (AAD). The multicenter, double-blind, placebo-controlled trial successfully randomized 424 patients across the USA and Europe, surpassing the original target of 375 participants. Patients are being treated with either 50mg or 100mg of Masupirdine or a placebo daily for 12 weeks.
Why this matters
This milestone is critical as it validates the company’s ability to execute complex global clinical trials. By exceeding enrollment targets, the firm demonstrates strong site engagement and participant interest. Masupirdine is a selective 5-HT6 receptor antagonist designed to provide an alternative to existing treatments like sedatives and antipsychotics, which often carry significant safety risks for elderly patients.
What changes now
The company has set clear milestones for the remainder of the study. The 'Last Patient Last Visit' (LPLV) is expected by December 2026, followed by a database lock by March 2027. Investors can look forward to the topline efficacy and safety data release in May 2027.
Risks to watch
As with all clinical-stage pharmaceutical companies, the primary risk remains the trial outcome. The efficacy and safety data in the final report will determine the commercial viability of Masupirdine. Failure to meet primary endpoints in the Phase-3 trial would represent a significant setback for the company’s pipeline value.
What to track next
Watch for updates on site performance or interim safety data monitoring that may precede the 2027 topline results. The market will closely track any shifts in the planned 2027 disclosure timeline.